Vectura reaches new milestone in VR315 project

Vectura Group, a pharma company specialising in treatments for respiratory diseases, has recorded revenues of three million dollars under an agreement signed a year ago for the development, manufacturing and commercialisation of VR315 with an international pharmaceutical company.

Vectura Group, a pharma company specialising in treatments for respiratory diseases, has recorded revenues of three million dollars under an agreement signed a year ago for the development, manufacturing and commercialisation of VR315 with an international pharmaceutical company.

The revenue total includes the realisation of $2.0m of deferred revenue which was received in March of this year.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.